65 related articles for article (PubMed ID: 20498639)
21. PREP1 deficiency downregulates hepatic lipogenesis and attenuates steatohepatitis in mice.
Oriente F; Cabaro S; Liotti A; Longo M; Parrillo L; Pagano TB; Raciti GA; Penkov D; Paciello O; Miele C; Formisano P; Blasi F; Beguinot F
Diabetologia; 2013 Dec; 56(12):2713-22. PubMed ID: 24052111
[TBL] [Abstract][Full Text] [Related]
22. Loss of CCDC6, the first identified RET partner gene, affects pH2AX S139 levels and accelerates mitotic entry upon DNA damage.
Merolla F; Luise C; Muller MT; Pacelli R; Fusco A; Celetti A
PLoS One; 2012; 7(5):e36177. PubMed ID: 22655027
[TBL] [Abstract][Full Text] [Related]
23. Loss of CCDC6 affects cell cycle through impaired intra-S-phase checkpoint control.
Thanasopoulou A; Stravopodis DJ; Dimas KS; Schwaller J; Anastasiadou E
PLoS One; 2012; 7(2):e31007. PubMed ID: 22363533
[TBL] [Abstract][Full Text] [Related]
24. Identification of potential prognostic biomarkers among gene models for coiled-coil domain-containing family members in hepatocellular carcinoma elucidates their influence on the hypoxia pathway and immune microenvironment.
Li J; Zhang D; Liu H; Wang D; Pan C; Biachi de Castria T; Mok SRS; Zhou Z; Yan C
J Gastrointest Oncol; 2023 Dec; 14(6):2559-2573. PubMed ID: 38196528
[TBL] [Abstract][Full Text] [Related]
25. High expression of CCDC6 in relation to unfavorable outcome and immune cells infiltration in hepatobiliary carcinoma.
Wu T; Jiang X; Xu B; Zhong Q; Zheng J; Zhang X; Wang Y
J Cancer; 2022; 13(12):3378-3395. PubMed ID: 36186907
[No Abstract] [Full Text] [Related]
26. The circ_FAM53B-miR-183-5p-CCDC6 axis modulates the malignant behaviors of papillary thyroid carcinoma cells.
Zhang C; Gu H; Liu D; Tong F; Wei H; Zhou D; Fang J; Dai X; Tian H
Mol Cell Biochem; 2022 Nov; 477(11):2627-2641. PubMed ID: 35598218
[TBL] [Abstract][Full Text] [Related]
27. Posttranslational Modifications in Thyroid Cancer: Implications for Pathogenesis, Diagnosis, Classification, and Treatment.
Broekhuis JM; James BC; Cummings RD; Hasselgren PO
Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406382
[TBL] [Abstract][Full Text] [Related]
28. The tumour suppressor CCDC6 is involved in ROS tolerance and neoplastic transformation by evading ferroptosis.
Morra F; Merolla F; Zito Marino F; Catalano R; Franco R; Chieffi P; Celetti A
Heliyon; 2021 Nov; 7(11):e08399. PubMed ID: 34841108
[TBL] [Abstract][Full Text] [Related]
29. OLFM4-RET fusion is an oncogenic driver in small intestine adenocarcinoma.
Liu W; Li H; Aerbajinai W; Botos I; Rodgers GP
Oncogene; 2022 Jan; 41(1):72-82. PubMed ID: 34675408
[TBL] [Abstract][Full Text] [Related]
30. Neuropilin-1 Expression Associates with Poor Prognosis in HNSCC and Elicits EGFR Activation upon CDDP-Induced Cytotoxic Stress.
Napolitano V; Russo D; Morra F; Merolla F; Varricchio S; Ilardi G; Di Crescenzo RM; Martino F; Mascolo M; Celetti A; Tamagnone L; Staibano S
Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359721
[TBL] [Abstract][Full Text] [Related]
31. Suppression of CCDC6 sensitizes tumor to oncolytic virus M1.
Liu Y; Li K; Zhu WB; Zhang H; Huang WT; Liu XC; Lin Y; Cai J; Yan GM; Qiu JG; Peng L; Liang JK; Hu C
Neoplasia; 2021 Jan; 23(1):158-168. PubMed ID: 33338804
[TBL] [Abstract][Full Text] [Related]
32. Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors.
Criscuolo D; Morra F; Giannella R; Cerrato A; Celetti A
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31242618
[TBL] [Abstract][Full Text] [Related]
33. CRISPR/Cas9-mediated Genomic Editing of Cluap1/IFT38 Reveals a New Role in Actin Arrangement.
Beyer T; Bolz S; Junger K; Horn N; Moniruzzaman M; Wissinger Y; Ueffing M; Boldt K
Mol Cell Proteomics; 2018 Jul; 17(7):1285-1294. PubMed ID: 29615496
[TBL] [Abstract][Full Text] [Related]
34. The rationale for druggability of CCDC6-tyrosine kinase fusions in lung cancer.
Cerrato A; Visconti R; Celetti A
Mol Cancer; 2018 Feb; 17(1):46. PubMed ID: 29455670
[TBL] [Abstract][Full Text] [Related]
35. The between Now and Then of Lung Cancer Chemotherapy and Immunotherapy.
Visconti R; Morra F; Guggino G; Celetti A
Int J Mol Sci; 2017 Jun; 18(7):. PubMed ID: 28653990
[TBL] [Abstract][Full Text] [Related]
36. The combined effect of USP7 inhibitors and PARP inhibitors in hormone-sensitive and castration-resistant prostate cancer cells.
Morra F; Merolla F; Napolitano V; Ilardi G; Miro C; Paladino S; Staibano S; Cerrato A; Celetti A
Oncotarget; 2017 May; 8(19):31815-31829. PubMed ID: 28415632
[TBL] [Abstract][Full Text] [Related]
37. miR-130b-3p Upregulation Contributes to the Development of Thyroid Adenomas Targeting CCDC6 Gene.
Leone V; Langella C; Esposito F; De Martino M; Decaussin-Petrucci M; Chiappetta G; Bianco A; Fusco A
Eur Thyroid J; 2015 Dec; 4(4):213-21. PubMed ID: 26835423
[TBL] [Abstract][Full Text] [Related]
38. Ccdc6 knock-in mice develop thyroid hyperplasia associated to an enhanced CREB1 activity.
Leone V; Langella C; Esposito F; Arra C; Palma G; Rea D; Paciello O; Merolla F; De Biase D; Papparella S; Celetti A; Fusco A
Oncotarget; 2015 Jun; 6(17):15628-38. PubMed ID: 25970781
[TBL] [Abstract][Full Text] [Related]
39. FBXW7 and USP7 regulate CCDC6 turnover during the cell cycle and affect cancer drugs susceptibility in NSCLC.
Morra F; Luise C; Merolla F; Poser I; Visconti R; Ilardi G; Paladino S; Inuzuka H; Guggino G; Monaco R; Colecchia D; Monaco G; Cerrato A; Chiariello M; Denning K; Claudio PP; Staibano S; Celetti A
Oncotarget; 2015 May; 6(14):12697-709. PubMed ID: 25885523
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
